The evolution of plasma-based therapeutics is accelerating – our FREE report cuts through the young blood hype for the lowdown on the latest therapies.
Our new report on young blood is just one of reports we have just made freely available on our website. In it we seek to understand the reality behind the blood plasma hype – is it really an elixir of youth? What role do chronokines play? What are the investment opportunities available?
Longevity.Technology: The appetite for tackling aging via the blood and support for the hypothesis that the circulatory system could be a key to full body regeneration are growing. Recent discoveries in murine models and other preclinical and clinical evidence have made headlines and on Longevity.Technology alone, we’ve covered Ambrosia overcoming its FDA warning, the University of Berkeley’s plasma dilution experiments and Nugenics Research’s 54% age reversal in animal study, as well as interviews with Harold Katcher and Irina Conboy.
However, there is a path to be steered between concerns about adopting therapeutics before rigorous clinical trials and the excitement that new potential therapies generates.
Our report navigates this path, and we invite you on the journey – and it’s absolutely free.
Our new report sets out the role for young blood plasma as a valid and scalable therapy for mitigating diseases of aging through medically valid rejuvenation techniques. It contains a deep dive for scientists into the pathways and interventions that could deepen knowledge for a start-up or scientist interested in the space and looking for an overall view into young blood, and an explanation for potential investors of the investment opportunities in young blood.
The science of young blood
Human physiology and disease are deeply and significantly integrated; organs and tissues once thought to act and behave largely independent of one another – such as the the brain and the gut – are now known to be co-dependent in nature in constant communication with one another. Pathologies that were once thought to be separate are now understood to be intimately connected.
These relationships are demonstrated by the rapid accumulation of comorbidities once an initial disease has been contracted; but what is the source of biological information that is being propagated across the body leading to everything going haywire? And how is this information being propagated?
Click here to download your free report.
The circulatory system – our blood – is packed with information that is distributed throughout the body and represents a powerful method of communication. Emerging evidence that suggests the body can co-opt the circulatory system to coordinate aging, and it does this via the secretion of factors called chronokines. Chronokines can be progeronic factors, meaning that they accelerate aging, or youth factors, meaning that they accelerate rejuvenation. Leveraging this could be significant, and indeed there are many companies developing therapeutics in the blood and circulation area are looking for chronokines in the plasma of the blood.
Factors that cells routinely secrete into the bloodstream to communicate are known as the body’s communicome. Aging is driven by an imbalance in plasma chronokines and a dysfunctional communicome. Plasma derivatives offer an opportunity to develop a wholly new paradigm for treating age-related disorders through the communicome, and there are plasma-based therapeutics that can be used to restore balance; our report delves into these, assessing the strengths and weaknesses.
We also consider heterochronic parabiosis, how to optimise the efficacy of plasma-based therapeutics, chronokine mimetics, the Goldilocks zone for plasma fractions, extracorporeal filters and many more. Our report covers stem cell signalling, finding out how old bodies can ‘remember’ to be young and intercellular signalling and how chronic inflammation, senescence and inflammaging can be ameliorated by plasma therapeutics.
Sign up for FREE to get access to all longevity reports.
The investment opportunity of young blood
Plasma therapies have significant potential to target multiple diseases of aging due to plasma’s regenerative capacity; currently, plasma-based therapies are comparatively expensive, but we will see price points dropping as technologies mature and more data is collected. Another upside of this is that it incentivises healthcare providers to cover costs and this in turn makes it more accessible to the general public.
Clearly there are worries and misconceptions about the ethical issues surrounding young blood – it’s hard to avoid images of vampires being conjured up, for example. However, there are a number of companies going through clinical trial phases to ensure the efficacy and safety of their plasma-based therapeutics, there are already approximately 200,000 plasma exchanges procedures performed worldwide each year, and the procedure is approved to treat more than 50 relatively uncommon diseases.
Our report highlights some of the most impactful disease markets where plasma-based therapeutics show promise based on both preclinical and clinical data.
Our report also dives into some of the companies in the space, looks at the regulation involved and covers how to make sense of the preclinical, clinical and non-clinical data in order to be better informed about the space.
Are we ready to administer young blood therapies? Download our free report to find out!
